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Abstract-The effect of calcitonin gene-related peptide (CGRP) on the cyclic nucleotide level in isolated mouse diaphragm was investigated.
CGRP at con centrations of up to 1 i M caused dose-dependent increases in cyclic AMP levels but had no effect on cyclic GMP levels. At 1 /tM, CGRP increased cyclic AMP levels by about 2.7-fold.
Moreover, in the presence of phosphodiesterase inhibitor (Ro 20-1724), CGRP still caused even greater dose-dependent increases in cyclic AMP levels. Even in the presence of propranolol, a beta-adrenergic antagonist, CGRP stimulated increased cyclic AMP levels.
In addition, specific binding of CGRP was observed in mouse diaphragm.
All these results suggest that CGRP increases intracellular cyclic AMP levels via a CGRP receptor but not the beta adrenergic receptor.
Calcitonin gene-related peptide (CGRP) is a peptide composed of 37 amino acids that is synthesized in nervous tissues by a different processing of the messenger RNA for calcitonin (1, 2) . A wide, but non-random distribution of CGRP-like immunoreactive structures in the central and peripheral nervous system has been demonstrated by immunocytochemical studies and radio immunoassay (2, 3) . CGRP has been shown to cause physiological responses (4) (5) (6) (7) (8) (9) and to have a binding site (10, 11) , suggesting that it is a neurotransmitter or neuromodulator. We observed a very wide distribution of CGRP in the central and peripheral nervous systems (3, (12) (13) (14) .
In these studies, we found that CGRP is localized in motor neurons and in nerve terminals of neuromuscular junctions of striated muscle where it coexists with acetylcholine (Ach) (9, 14) . Further more, we observed that CGRP enhances the contraction of striated muscle (9) . These findings suggest that it may function as a modulator of the contraction induced by Ach and be important in neuromuscular trans mission.
It has been shown that enhancement of muscle contraction is caused by an elevation of the intracellular cyclic AMP concentration (15) (16) (17) (18) .
Therefore, in the present study, using a mouse diaphragm preparation, we examined the effect of CGRP on striated muscle and its relation to the level of cyclic AMP. In addition, we investigated the existence of specific CGRP binding sites in striated muscle.
Materials and Methods
Assay of cyclic AMP in mouse diaphragm: Male DDY mice weighing about 30 g were used.
Under anesthetization with pen tobarbital (Nembutal, 50 mg/kg, i.p.), diaphragms were rapidly excised, separated from adjacent tissues, and cut in two sagitally. Until the beginning of preincubations, the preparations were stocked in Krebs-Ringer solution (bubbled with 5% C02 in 02 and kept at 4°C). The preparations were pre incubated in Krebs-Ringer solution bubbled with 5% C02 in 02 at 37 °C for 5 min, and then ** To whom correspondence should be addressed .
incubated with CGRP and other drugs for 3 min. The tissues were then rapidly frozen in liquid nitrogen and stored at -80°C for assay of cyclic AMP. The frozen tissues were weighed and homogenized in 10 volumes of HCI (0.1 N) in a motor-driven micro homogenizer at 0°C (Tokai Irika Co.). The homogenate was centrifuged at 25,000 g for 15 min at 4°C and the supernatant was used for cyclic AMP assay. Cyclic AMP was measured with a kit from Yamasa Shoyu Co. using a method for radioimmunoassay involving prior succinylation of samples. Assay of cyclic GMP in mouse diaphragm: Cyclic GMP was similarly measured with a kit from Yamasa Shoyu Co., also based on radioimmunoassay involving prior succini lation.
Assay of CGRP binding: For binding assay, the homogenate was centrifuged for 10 min at 1000 g. The pellet was discarded and the supernatant was centrifuged for 10 min at 15,000 g. The pellet was washed and recentrifuged twice. The final pellet was resuspended in 50 mM Hepes/Tris buffer pH 7.4 (0.5 g wet original tissue per 1 ml buffer). The binding assay was carried out in a siliconized assay tube which contained 50 mM Hepes/Tris, 1 % BSA, 10 pM 1251 CGRP and various concentrations of cold CGRP in a total volume of 0.5 ml. The incubation was started by adding membrane protein and was carried out for 60 min at 6°C. After incubation, the samples were centrifuged for 5 min using an Eppendorf 54BS table centrifuge and the supernatant was sucked off. The pellet was washed with 0.5 ml ice cold buffer up to 3 times. A 5 mm section of the assay tube containing the pellet was cut off, put into a 3 ml plastic tube and counted in a gamma counter.
Drugs
Results
Effects of CGRP on the tissue levels of cyclic AMP and cyclic GMP: Incubation of the hemi-diaphragm with 0.1 i M CGRP caused 1.8-fold increases in cyclic AMP levels within 1 min. The peak level was maintained for at least 10 min (Fig. 1) . Con centrations of from 10 n M to 1 flM CG R P caused dose-dependent increases in cyclic AMP levels ( Fig. 2) : even at 1 /cM CGRP cyclic AMP levels (266% of the control) did not reach a plateau (Fig. 2A) .
Cyclic G M P levels (44.6±4.7 fmol/mg tissue, n=4), however, were not significantly affected by 1 ,aM CGRP (48.2±8.3 fmol/mg tissue, n=4), even by the end of 3 min, at which time cyclic AMP levels had already risen dramatically (Fig. 1) .
Effect of phosphodiesterase inhibitors on CGRP-induced increases in cyclic AMP levels: The effects of the phosphodiesterase inhibitors theophylline (1 mM), papaverine (30 aM) and Ro 20-1724 (0.3 mM) on level of cyclic AMP were investigated. These compounds all raised the tissue levels of cyclic AMP, as shown in Table 1 . Ro 20 1724, which had the greatest effect, increased the cyclic AMP level 6.6-fold during a 3 min incubation, while other compounds increased it about 2-fold. I n the presence of these compounds, CGRP (0.1 ,u M) increased the 
CGRP(+)/CGRP(-)). The acti vation ratios ((+)/(-))
in the presence of phosphodiesterase inhibitors were higher than in their absence. Figure 3 shows the dose-dependent increase of cyclic AMP produced by CGRP in the presence of Ro 20 1724.
Effect of propranolol on CGRP-induced increases in cyclic AMP levels: Beta adrenergic agonists are known to increase the cyclic AMP level and enhance con traction of striated muscle. Therefore, we examined whether CGRP had an effect via the beta-adrenergic system. In the presence of propranolol (1 PM), CGRP increased the cyclic AMP level 2.0-fold (Table  2) . Moreover, CGRP (0.1 ,uM) enhanced muscle contraction in response to under direct stimu lation of the diaphragm even in the presence of propranolol
(1 itM) (data not shown). These findings indicate that the effects of CGRP on the cyclic AMP level and muscle contraction are not mediated by the beta adrenergic system.
Assay of CGRP binding: Specific binding of CGRP was observed. Figure 3 shows that bound 1251-CGRP was displaced with cold CGRP, characterized by IC50-value of 50 nM.
Discussion
Several biological effects of CGRP have been reported (4-9). Previously we reported that CGRP coexists with Ach in motor nuclei and neuromuscular junctions, and enhances the contraction of the striated muscle stimu lated either directly or by nerves (9, 14) . But little is known about the mechanism of this effect.
In the present study, we examined whether the effect of CGRP on muscle contraction was related to cyclic AMP accumulation.
Results showed that CGRP increased cyclic AMP levels in mouse diaphragm; at concentrations of up to 1 /.eM, it increased tissue levels of cyclic AMP up to 2.7-fold in a dose dependent manner. Previously, we reported that the enhancement of twitch contractions of diaphragmatic muscle induced by CGRP during nerve or direct stimulation first oc Table 2 . Effect of CGRP on cyclic AMP levels in mouse diaphragm in the presence and absence of nrnoranolol curred within one minute (9, 14) . As shown in Fig. 1 , its effect of CGRP on cyclic AMP levels was sufficient to produce prompt enhancement of the twitch contraction.
Theophylline, papaverine and Ro 20-1724, which are phosphodiesterase inhibitors, caused significant increases in tissue levels of cyclic AMP (Table 1) . Moreover, CGRP increase cyclic AMP levels more in the presence of these phosphodiesterase in hibitors than in their absence (Fig. 2B and Table 1 ). These data support the existence of CGRP-stimulated adenylate cyclase activity in the membrane fraction of rat diaphragm (H. Kobayashi et al., unpublished data).
In striated muscle, beta-adrenergic ago nists are reported to increase the level of cyclic AMP, and beta-adrenergic agonists, dibutyryl cyclic AMP and phosphodiesterase inhibitors all enhance muscle contraction under either nerve or direct stimulation (15 18 ). Under such conditions, adrenergic agonists might enhance twitch contraction of muscle mediated by an intracellular cyclic AMP. Increases in cyclic AMP levels may well mediate diverse effects on the metabolism of striated muscle cells, such as the defatigu ing effect of adrenaline. Enhanced twitch contraction is probably one result of these diverse effects. Our results with CGRP and the previously reported effects of beta agonists and dibutyryl-cyclic AMP indicate that enhancement of contraction may be relate to increased intracellular levels of cyclic AMP.
The effect of CGRP was not mediated by beta-adrenergic receptors, because it in creased cyclic AMP levels and enhanced muscle contraction even in the presence of propranolol (data not shown). We reported previously that the effect of CGRP was also not mediated via the nicotinic receptor (9) . I n this study, we showed that specific CG R P binding sites exist on the muscle membrane. Accordingly, CGRP may activate adenylate cyclase in the muscle by binding to a CGRP receptor on the muscle plasma membrane.
